ABSCF Stock Chart & Stats
$1.12
$0.00(0.00%)
At close: 4:00 PM EDT
$1.12
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$1.12 - $1.45
Previous CloseN/A
Volume200.00
Average Volume (3M)0.00
Market Cap
$83.16M
Enterprise Value$55.46M
Total Cash (Recent Filing)$10.18M
Total Debt (Recent Filing)$4.24M
Price to Earnings (P/E)―
Beta0.05
Next Earnings
Sep 25, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding96,530,785
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.73
Price to Book (P/B)-5.48
Price to Sales (P/S)80.33
P/FCF Ratio-20.63
Enterprise Value/Market Cap0.67
Enterprise Value/Revenue47.24
Enterprise Value/Gross Profit77.03
Enterprise Value/Ebitda-45.57
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.17
Revenue Forecast (FY)$1.38M
Bulls Say, Bears Say
Bulls Say
Recent Revenue GrowthRevenue growth in recent years indicates some progress in commercial or collaboration-related activity. Sustaining this trend could improve operating leverage, although the current revenue base remains small and profitability has not yet followed.
Substantial Debt ReductionThe sharp reduction in debt lowers contractual financing pressure and may improve financial flexibility relative to prior years. However, this benefit is constrained by negative equity and continuing cash consumption, which still create funding risk.
Proprietary Drug Development PlatformA proprietary pipeline gives AB Science potential to retain product economics through future approvals, licensing, milestones, or royalties. Masitinib’s multi-indication focus may broaden opportunity, though value remains dependent on clinical and regulatory success.
Bears Say
Persistently Negative Shareholder EquityNegative equity signals a fragile capital structure and limited balance-sheet protection for creditors or shareholders. It reduces financial flexibility and leaves the company highly sensitive to further losses, dilution, or the need for additional financing.
Renewed Operating And Free-cash-flow BurnThe return to sizable cash burn after a modestly positive 2024 indicates that internal cash generation is not dependable. Persistent outflows can shorten the funding runway and constrain investment in clinical development without external capital.
Deep And Persistent UnprofitabilityOngoing operating and net losses show that the business remains far from a self-sustaining earnings model. With no identified material marketed-product revenue stream, profitability depends on clinical progress, approvals, and future commercialization or partnering.
AB Science SA News
ABSCF FAQ
What was AB Science SA’s price range in the past 12 months?
AB Science SA lowest stock price was $1.12 and its highest was $1.45 in the past 12 months.
What is AB Science SA’s market cap?
AB Science SA’s market cap is $83.16M.
When is AB Science SA’s upcoming earnings report date?
AB Science SA’s upcoming earnings report date is Sep 25, 2026 which is in 29 days.
How were AB Science SA’s earnings last quarter?
AB Science SA released its earnings results on May 13, 2026. The company reported -$0.08 earnings per share for the quarter, the consensus estimate of -$0.08 by $0.
Is AB Science SA overvalued?
According to Wall Street analysts AB Science SA’s price is currently Overvalued.
Does AB Science SA pay dividends?
AB Science SA does not currently pay dividends.
What is AB Science SA’s EPS estimate?
AB Science SA’s EPS estimate is -0.08.
How many shares outstanding does AB Science SA have?
AB Science SA has 96,530,785 shares outstanding.
What happened to AB Science SA’s price movement after its last earnings report?
AB Science SA reported an EPS of -$0.08 in its last earnings report, expectations of -$0.08. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of AB Science SA?
Currently, no hedge funds are holding shares in ABSCF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
AB Science SA
AB Science S.A. is a pharmaceutical company dedicated to the discovery, development, and commercialization of protein kinase inhibitors for applications in both human and animal health. Its primary drug candidate, masitinib, a tyrosine kinase inhibitor, is currently undergoing late-stage (Phase III) clinical investigations for a range of serious conditions including prostate cancer, pancreatic cancer, amyotrophic lateral sclerosis (ALS), multiple sclerosis, Alzheimer's disease, severe asthma, and mastocytosis. Additionally, masitinib is being evaluated in Phase II clinical trials for the treatment of Covid-19. The company's pipeline also features AB8939, a synthetic microtubule destabilizer aimed at treating acute myeloid leukemia, and AB20001, which is in Phase 2 trials to assess the safety and efficacy of masitinib combined with isoquercetin in hospitalized patients experiencing moderate to severe COVID-19. Masitinib is sold under the brand name Masivet in the European market. AB Science S.A. was founded in 2001 and is based in Paris, France.